Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center

Table 2 Summary of changes from baseline at 3 months, 6 months and 9 months in all patients

Marker	3 months				6 months				9 months
	n	Mean change	95%CI	P value	n	Mean change	95%CI	P value	n	Mean change	95%CI	P value
Albumin (g/L)	51	+0.92	0.04-1.81	0.042	37	+1.13	0.13-2.12	0.026	22	+2.13	0.92-3.34	< 0.001
CRP (mg/L)	51	-1.75	-9.06-5.56	0.639	37	+1.5	-6.52-9.52	0.714	22	-6.85	-16.46-2.76	0.163
FCP (μg/g)	33	-253.3	-541.48-34.95	0.085	22	-141.3	-468.65-186.08	0.398	12	-193.5	-601.82-214.86	0.353
HBI	48	-2.5	-3.32 to -1.76	< 0.001	32	-3.0	-3.87 to -2.08	< 0.001	19	-4.36	-5.51 to -3.20	< 0.001

CRP: C-reactive protein; FCP: Faecal calprotectin; HBI: Harvey-Bradshaw Index; CI: Confidence interval.